0000033086 00000 n Drug information provided by: IBM Micromedex It is very important that your doctor check your progress at regular visits to make sure this medicine is working properly and to check for unwanted effects .

0000033579 00000 n 0000050151 00000 n The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil. A nonlinear correlation between the verapamil dose administered and verapamil plasma levels does exist. Tilt-table testing (60 degrees) was not able to induce orthostatic hypotension.Elevations of transaminases with and without concomitant elevations in alkaline phosphatase and bilirubin have been reported. H�d�M����|��st�A����!r >� q�{��k�����}V�(�(3=�k�=�3}�y���~|��t{��������������X��~���6�ǧ�����=޽z���������ۛ7w���|�㧧�o���o��? In patients with hypertrophic cardiomyopathy (IHSS), alpha-adrenergic agents (phenylephrine HCl, metaraminol bitartrate, or methoxamine HCl) should be used to maintain blood pressure, and isoproterenol and norepinephrine should be avoided. Grapefruit juice interacts with the drug and can affect heart rate and blood pressure. Verapamil HCl is not chemically related to other cardioactive drugs.Inactive ingredients include microcrystalline cellulose, corn starch, gelatin, hydroxypropyl cellulose, hypromellose, iron oxide colorant, lactose, magnesium stearate, polyethylene glycol, talc, and titanium dioxide.Calan is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) that exerts its pharmacologic effects by modulating the influx of ionic calcium across the cell membrane of the arterial smooth muscle as well as in conductile and contractile myocardial cells.The precise mechanism of action of Calan as an antianginal agent remains to be fully determined, but includes the following two mechanisms:Electrical activity through the AV node depends, to a significant degree, upon calcium influx through the slow channel. 362 0 obj <> endobj

Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. CALAN (verapamil HCl) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) available for oral administration in film-coated tablets containing 40 mg, 80 mg, or 120 mg of verapamil hydrochloride. You could have more side effects. It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly.Hypotension and bradyarrhythmias have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class.Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. 0000001932 00000 n

Verapamil (Calan, Verelan) In some cases, your doctor might prescribe a calcium channel blocker with other high blood pressure medications or with cholesterol-lowering drugs such as statins. Calan (verapamil HCl) is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) available for oral administration in film-coated tablets containing 80 mg or 120 mg of verapamil hydrochloride.The structural formula of verapamil HCl is:Benzeneacetonitrile, α-[3-[[2-(3,4-dimethoxyphenyl)ethyl] methylamino]propyl]-3,4-dimethoxy-α-(1-methylethyl) hydrochlorideVerapamil HCl is an almost white, crystalline powder, practically free of odor, with a bitter taste. 0000004943 00000 n <<39AF13E7E9E9C84C8E157FD36FC0E333>]>> 0000005362 00000 n 0000004810 00000 n Intravenous verapamil HCl is contraindicated in: 1. By decreasing the influx of calcium, Calan prolongs the effective refractory period within the AV node and slows AV conduction in a rate-related manner.

When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, should each be titrated carefully to avoid excessive cardiovascular depression.Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). In patients with hepatic insufficiency, metabolism is delayed and elimination half-life prolonged up to 14 to 16 hours (see After four weeks of oral dosing (120 mg q.i.d. }���vߟ����\���_��z�����?�?��5������~=|��~)o�:����s{�n�������-�R��\�XO���u��������~~��[����ks}����ktx��%&+��5���oV�1b0�(F1������X�����ŗ�Mƿ��c6��l���X�"V��U���.vq�C��8�%.q�[��~��o��Q ��| ��g x��g�x��g�x��g�x��g�x��g�x��g�x��g�x��g�x��g�yF��g�yF��g�yF��g�yF��g�yF��g�yF��g�yF��g�yF��g�yF��g�yF��g�yF��g�yF��g�x&��g�x&��g�x&��g�x&��g�x&��g�x&��g�x&��g�x&��g�x&��g�x&��g�x&��g�x&��g�yf��g�yf��g�yf��g�yf��g�yf��g�yf��g�yf��g�yf��g�yf��g�yf��g�yf��g�yf��g�y� It may be necessary to decrease the dosage of verapamil when it is administered to patients with attenuated neuromuscular transmission.About 70% of an administered dose of verapamil is excreted as metabolites in the urine.

Use Calan (verapamil injection) as ordered by your doctor.